Experts and the Drug Industry
March 4, 2005 08:50

The center found that at least 10 of the 32 panel members had consulted for or received research support from Pfizer, which makes Celebrex and Bextra; Merck, which makes Vioxx; or Novartis, which is seeking approval for a similar drug. Had the votes of those 10 scientists been excluded, the panel would have favored withdrawing Bextra from the market and blocking the return of Vioxx. Only Celebrex would have been deemed safe to use. See: http://www.nytimes.com/2005/03/04/opinion/04fri3.html?th

Three years after the drug industry said it would stop showering doctors with expensive gifts, a top federal drug official told a Senate panel on Thursday that such marketing efforts continued. see: http://www.nytimes.com/2005/03/04/politics/04fda.html?th

For Immediate Release: March 4, 2005 Drug Approved Through Fast Track, But Failed to Reduce Death Rate WASHINGTON, D.C. - Iressa, a drug approved to treat non-small cell lung cancer, should be pulled from the market because it does not improve survival... (Read Article)